Semaglutide News and Research

Latest Semaglutide News and Research

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

More than two-thirds of all type-2 diabetes patients do not achieve good control of their disease with the first-line medication metformin combined with second-line insulin shots.

2 Mar 2016

Isomaltulose more suitable than table sugar for people with type 2 diabetes

Potsdam-Rehbruecke - Like sucrose (table sugar), the natural disaccharide isomaltulose (PalatinoseTM) consists of glucose and fructose, but it is apparently more suitable for people with type 2 diabetes with regard to regulating blood glucose levels.

17 Feb 2016

Penn investigators explore new treatment option for cocaine dependence

In the ongoing fight against drug addiction, researchers from the University of Pennsylvania's School of Nursing and Perelman School of Medicine have discovered a unique application for an FDA-approved drug currently used for obese patients and type 2 diabetics: treatment for cocaine dependence.

11 Feb 2016

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels.

8 Feb 2016

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program.

18 Jan 2016

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.

7 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in their efficacy and safety profiles, according to new research by the University of Leicester.

10 Dec 2015

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP-1 receptor agonist do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed combination offers an added benefit over the appropriate comparator therapy (ACT).

19 Nov 2015

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

New generation of incretin-based medicines allows coordinated action against diabesity

The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases.

28 Oct 2015

Type-2 diabetes medication can affect the brain's reward system, reduce intake of food

Many studies have focused on how much we eat when we are hungry, but sometimes we eat just to feel better. A new dissertation at Sahlgrenska Academy shows that medication used for type-2 diabetes wich mimics the gut-brain hormone glucagon-like peptide-1, can affect the brain's reward system and reduce the intake of food.

29 Sep 2015

Medication used for diabetes could be a valuable tool for treating alcohol dependence

A new study on mice and rats at Sahlgrenska Academy shows that a medication used for diabetes and obesity also could be a valuable tool for the treatment of alcohol dependence.

25 Sep 2015

New study highlights gap in scientific knowledge about some diabetes drugs

A gap in scientific knowledge about a family of drugs that are used to treat Type 2 diabetes has been highlighted in a new study.

21 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

Semaglutide News and Research

Latest Semaglutide News and Research

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Isomaltulose more suitable than table sugar for people with type 2 diabetes

Penn investigators explore new treatment option for cocaine dependence

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

Diabetes drug liraglutide ineffective in patients with advanced heart failure

New generation of incretin-based medicines allows coordinated action against diabesity

Type-2 diabetes medication can affect the brain's reward system, reduce intake of food

Medication used for diabetes could be a valuable tool for treating alcohol dependence

New study highlights gap in scientific knowledge about some diabetes drugs

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Ardelyx reports net income of $9.0 million for second quarter 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Semaglutide News and Research

Latest Semaglutide News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in